What are the differences between typical hemolytic uremic syndrome (HUS) and atypical hemolytic uremic syndrome (aHUS), and how are they diagnosed?

Typical vs Atypical HUS: Key Differences and Diagnostic Approach

Typical HUS (STEC-HUS) is caused by Shiga toxin-producing E. coli infection and typically follows 4-5 days after diarrhea onset, while atypical HUS (aHUS) is a complement-mediated thrombotic microangiopathy caused by dysregulated alternative complement pathway activation, presenting with simultaneous or very short diarrhea duration if present at all. 1, 2

Core Pathophysiologic Differences

Typical HUS (STEC-HUS)

• Etiology: Shiga toxin from E. coli O157:H7 (most common) or other STEC strains 2, 3
• Mechanism: Direct endothelial damage from bacterial toxin
• Timing: Appears at the END of gastrointestinal illness (4-5 days after diarrhea onset) 1
• Age: Predominantly children
• Prognosis: Generally self-limited with supportive care 2

Atypical HUS (aHUS)

• Etiology: Uncontrolled alternative complement pathway activation 1, 2
• Mechanism: Genetic mutations (60% of cases) in complement regulatory proteins (CFH, MCP, CFI, C3, CFB, THBD, DGKE) or anti-factor H autoantibodies (6-10%) 1, 4
• Timing: Diarrhea appears SIMULTANEOUSLY with HUS or very brief duration if present 1
• Age: Any age, though more frequent in childhood (approximately 10% of pediatric cases) 1
• Prognosis: High mortality (up to 20%) and progression to ESRD (50%) without complement inhibition 4

Diagnostic Algorithm

Step 1: Establish TMA Diagnosis

All HUS types present with the classic triad 1:

• Microangiopathic hemolytic anemia: Negative Coombs test, elevated LDH, reduced haptoglobin, schistocytes on blood smear
• Thrombocytopenia: Platelets <150,000/mm³ or 25% reduction from baseline
• Organ damage: Elevated creatinine, hematuria, proteinuria (primarily renal)

Critical caveat: In nearly 50% of cases at onset, not all three signs are clearly present 1. In newborns, aHUS may present without thrombocytopenia, anemia, OR elevated creatinine 1.

Step 2: Urgent Exclusion of TTP

Obtain ADAMTS13 activity level immediately (should be available within hours) 1, 5:

• ADAMTS13 <10%: TTP diagnosis → plasma exchange
• ADAMTS13 >10%: Proceed to differentiate typical vs atypical HUS

This distinction is life-critical as TTP requires plasma exchange while aHUS does not respond to this therapy 5.

Step 3: Differentiate Typical from Atypical HUS

First-Line Tests 1:

• Stool culture and PCR for Shiga toxins (including STEC O157:H7)
• Serology for anti-lipopolysaccharide antibodies
• Clinical history:
  • Bloody diarrhea 4-5 days BEFORE HUS onset → typical HUS
  • Simultaneous diarrhea and HUS OR no diarrhea → suspect aHUS

Complement Workup for aHUS 1, 6:

First-level tests:

• C3, C4 levels
• Factor H and Factor I plasma concentrations
• Anti-factor H antibodies
• sC5b-9 (elevated indicates complement overactivation) 7

Second-level tests:

• Genetic screening: CFH, CFHR1-5, C3, CD46 (MCP), CFI, CFB, THBD, DGKE via next-generation sequencing 1
• MCP expression on leukocytes 4

Important limitation: 40-50% of aHUS patients have NO identifiable mutation or autoantibody, but this does NOT exclude aHUS diagnosis 1, 8. The absence of complement abnormalities cannot rule out complement-mediated disease.

Step 4: Exclude Secondary Causes

Rule out other TMA triggers 1, 2:

• Streptococcus pneumoniae infection
• Autoimmune diseases (ANA, ANCA, anti-dsDNA)
• Malignancy
• Drugs (chemotherapy, calcineurin inhibitors)
• Pregnancy/postpartum
• Transplantation
• HIV, H1N1, SARS-CoV-2 1

Critical Diagnostic Pitfalls

1. Pediatric patients: Both typical and atypical HUS can present with diarrhea. The KEY distinguishing feature is timing - if diarrhea and HUS appear simultaneously or within a very short period, suspect aHUS over STEC-HUS 1.

2. Normal complement levels do not exclude aHUS: Over 40% have no detectable complement defect 1, 8.

3. Genetic variants of uncertain significance (VUS): Found in 30-40% of patients. Require functional assays and biomarker analysis to determine pathogenicity 9.

4. Creatinine interpretation in children: Must be assessed relative to age-appropriate norms 1.

5. Time-sensitive decision: Treatment must be initiated within 4-8 hours of diagnosis, as delays increase mortality and morbidity 1. Given diagnostic uncertainty and the devastating consequences of untreated aHUS, if STEC is ruled out and ADAMTS13 >10%, empiric complement inhibition should be strongly considered while awaiting genetic results.

Treatment Implications

• Typical HUS: Supportive care (hydration, transfusions, dialysis if needed) 2, 3
• Atypical HUS: Complement inhibition with eculizumab or ravulizumab is standard of care 1, 4, 7, 6. Plasma therapy has no proven efficacy and should not delay complement inhibition 5, 4.

The distinction between typical and atypical HUS is not academic - it determines whether a patient receives life-saving complement inhibition versus supportive care alone, directly impacting mortality and progression to end-stage renal disease 4, 9.